National Pension Service Increases Position in Regeneron Pharmaceuticals, Inc. $REGN

National Pension Service boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 278,135 shares of the biopharmaceutical company’s stock after purchasing an additional 7,069 shares during the period. National Pension Service owned about 0.26% of Regeneron Pharmaceuticals worth $156,387,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. State Street Corp raised its holdings in shares of Regeneron Pharmaceuticals by 0.9% in the 2nd quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after acquiring an additional 42,343 shares in the last quarter. Dodge & Cox increased its stake in Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Franklin Resources Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.6% in the second quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock worth $1,214,585,000 after buying an additional 36,821 shares during the period. Loomis Sayles & Co. L P increased its position in shares of Regeneron Pharmaceuticals by 18.6% in the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after acquiring an additional 305,089 shares during the period. Finally, Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $628,151,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Company beat Q4 revenue and EPS estimates (qtrly revenue $3.88B; EPS $11.44 vs. consensus ~$10.74), helped by Dupixent and Eylea HD sales — a near-term fundamental driver supporting the stock. GlobeNewswire – Q4 Results
• Positive Sentiment: Board raised the quarterly dividend to $0.94 (a ~6.8% increase vs. prior $0.88), signaling confidence in cash flow and making the stock slightly more attractive to income-focused investors.
• Positive Sentiment: Analyst optimism persists — Raymond James reiterated a Buy and set an $870 target; Evercore/ISI and others have also lifted targets, which can support demand on dips. TipRanks – Raymond James
• Positive Sentiment: Pipeline update: management highlighted an experimental obesity drug with added cholesterol-lowering benefits that could differentiate it in a crowded market — a potential medium-term growth driver. Reuters – Obesity drug story
• Neutral Sentiment: Full earnings materials and the Q4 earnings call transcript are available for deeper detail — useful for investors who want guidance commentary and pipeline timing. Seeking Alpha – Call Transcript
• Negative Sentiment: Despite the beats, EPS declined year-over-year (from $12.07 to $11.44) as higher expenses weighed on profitability — a headline that likely pressured sentiment. Reuters – Profit beat but EPS down YoY
• Negative Sentiment: Core Eylea weakness and investor concerns about sustainability of growth prompted some sell-side caution and profit-taking even after the beat, which helps explain the share decline today. MSN – Why shares fell

Insider Activity at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Down 1.1%

Regeneron Pharmaceuticals stock opened at $741.45 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The business’s 50-day simple moving average is $758.39 and its two-hundred day simple moving average is $650.56. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The company has a market cap of $77.93 billion, a PE ratio of 17.76, a PEG ratio of 1.95 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the business earned $12.07 earnings per share. The company’s revenue was up 2.5% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a dividend of $0.94 per share. The ex-dividend date is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Canaccord Genuity Group lifted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. HSBC began coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 target price on the stock. Finally, BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $784.77.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.